Volume 11, Number 6—June 2005
Research
Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs
John M. Stelling*†
, Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
, Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
Table 2
Odds ratios (OR) and 95% confidence intervals (CI) from multivariate analysis of risk factors for nonsusceptibility in Escherichia coli, 1997–2001*
| Drug | Factor | OR (95% CI) | p value |
|---|---|---|---|
| Cefepime (18,239 isolates) | Southern Europe | 2.23 (1.08–4.69) | 0.034 |
| Latin America | 4.82 (2.58–9.012) | <0.001 | |
| North America | 0.35 (0.16–0.76) | 0.008 | |
| Western Pacific | 6.39 (1.98–20.56) | 0.002 | |
| Age group | 1.74 (1.09–2.79) | 0.021 | |
| Intensive care unit | 2.84 (1.93–4.17) | <0.001 | |
| Ceftazidime (19,404 isolates) | Southern Europe | 2.20 (1.20–4.06) | 0.011 |
| Latin America | 4.79 (2.83–8.12) | <0.001 | |
| Age group | 1.94 (1.38–2.75) | <0.001 | |
| Intensive care unit | 2.25 (1.69–3.01) | <0.001 | |
| Ciprofloxacin (19,320 isolates) | Northern Europe | 1.62 (1.18–2.23) | 0.003 |
| Southern Europe | 2.99 (2.27–3.93) | <0.001 | |
| Latin America | 3.76 (2.93–4.84) | <0.001 | |
| North America | 0.77 (0.60–0.99) | 0.046 | |
| Western Pacific | 3.07 (1.63–5.76) | <0.001 | |
| Male | 1.46 (1.26–1.68) | <0.001 | |
| Age group | 0.39 (0.29–0.52) | <0.001 | |
| Year | 1.14 (1.07–1.21) | <0.001 | |
| Gentamicin (18,773 isolates) | Latin America | 2.44 (1.86–3.20) | <0.001 |
| North America | 0.74 (0.56–0.97) | 0.027 | |
| Western Pacific | 4.64 (2.66–8.09) | <0.001 | |
| Male | 1.28 (1.09–1.52) | 0.004 | |
| Age group | 1.47 (1.15–1.88) | 0.002 | |
| Intensive care unit | 1.23 (1.01–1.51) | 0.042 | |
| Piperacillin/tazobactam (19,261 isolates) | Southern Europe | 2.01 (1.38–2.92) | <0.001 |
| Latin America | 2.18 (1.60–2.96) | <0.001 | |
| Western Pacific | 2.11 (1.01–4.40) | 0.046 | |
| North America | 0.73 (0.54–0.99) | 0.040 | |
| Male | 1.33 (1.09–1.61) | 0.004 | |
| Year | 0.74 (0.68–0.81) | <0.001 | |
| Intensive care unit | 1.51 (1.24–1.92) | <0.001 | |
| Tobramycin (18,416 isolates) | Southern Europe | 1.43 (1.00–2.05) | 0.047 |
| Latin America | 3.09 (2.31–4.13) | <0.001 | |
| Western Pacific | 3.42 (1.77–6.63) | <0.001 | |
| North America | 0.70 (0.52–0.94) | 0.019 | |
| Male | 1.31 (1.10–1.57) | 0.003 | |
| Age group | 1.66 (1.30–2.13) | <0.001 | |
| Intensive care unit | 1.37 (1.11–1.69) | 0.003 |
*Logistic regression models simultaneously controlled for geographic region, age categories, sex, intensive care unit status, year of specimen, and reporting system. Only significant associations are presented. No significant relationships between nonsusceptibility and reporting system (MYSTIC vs. SENTRY) were found.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.